The modified stem cells might slow disease, too, though the trial was too small to say for sure.
Atomic-level analysis of the protein’s C-terminal end suggests a floppy region key for the delicate process of forming functional oligomers. Mutate it slightly, and it becomes an aggregating machine.
The FTC imposed a $2 million fine on Lumos Labs for overstating the benefits of the company’s Lumosity brain-training software.
The drug benefits some patients with mild amyotrophic lateral sclerosis, and is approved in Japan.
Scientists propose and test criteria to detect this treatable disorder without a brain biopsy.
Do α- and γ-secretase band together to cleave substrates such as the amyloid precursor protein?
Alzforum looks back on a year of developments.
When clinicians and pathologists argue, sometimes genetics can settle the dispute. How about DLB?
How α-synuclein aggregates spread, quite possibly starting in the nose in some people, sets DLB apart from its better-known cousins, Alzheimer’s and Parkinson’s.
In transgenic mice, revving up proteasome function lowered tau deposits and improved memory.
Nicastrin selects substrates for γ–secretase by turning away proteins with large ectodomains.
In dementia with Lewy bodies, basic scans are used in routine diagnosis. Multimodal imaging and new PET tracers for affected neurotransmitters of pathological deposits in the brain and gut are entering research settings.
At a DLB meeting, scientists reported progress in disentangling the notorious overlap in symptoms and pathology in this quintessential spectrum disease. (Hint: tangles are bad.)
Researchers will follow former football players at risk for the disorder to identify the best biomarkers and clinical criteria.
Studies find that a drug in cough syrup can improve symptoms, and that radiation therapy safely shuts off a salivary gland.